Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.31 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
| ▸ | TYMP | P19971 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13134723 | 1.00 | THRB (0.35) | THRBPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL13134725 | 1.00 | THRB (0.35) | THRBPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL2814951 | 0.87 | ABL1 (0.39) | THRBPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL13134717 | 0.86 | THRB (0.33) | THRBPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL2838277 | 0.85 | THRB (0.34) | THRBPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL2816907 | 0.83 | TYMP (0.40) | THRBPOLBP2RY6P2RY2P2RY4 | |
| SCHEMBL2838908 | 0.79 | MEN1 (0.31) | POLBP2RY6P2RY2P2RY4ABL1 | |
| SCHEMBL2812096 | 0.79 | MEN1 (0.31) | POLBP2RY6P2RY2P2RY4ABL1 | |
| SCHEMBL800270 | 0.79 | P2RY6 (0.33) | POLBP2RY6P2RY2P2RY4ABL1 | |
| SCHEMBL800290 | 0.77 | P2RY6 (0.33) | POLBP2RY6P2RY2P2RY4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2623104-A1 | Substituted nucleoside and nucleotide analogs | Alios Biopharma, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2623104-A1 | Substituted nucleoside and nucleotide analogs | Alios Biopharma, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | THRB 3293/4885POLB 135/4885P2RY6 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.